Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden.
Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics Center for Alzheimer Research, Karolinska Institutet, Stockholm, Sweden.
J Alzheimers Dis. 2020;75(1):321-335. doi: 10.3233/JAD-200028.
The 42 amino acids long amyloid-β peptide, Aβ42, may initiate a cascade of events leading to the severe neurodegeneration observed in Alzheimer's disease (AD) brain. However, the underlying molecular mechanisms remain to be established.
To find early Aβ42-induced AD related mechanisms, we performed a brain proteomics time-course study on a novel App knock-in AD mouse model, AppNL-F, expressing high levels of Aβ42 without AβPP overexpression artifacts.
Hippocampus and cortex were analyzed separately by using 18O-labelling mass spectrometry to reveal alterations in protein levels. Pathway analysis of proteomics data was used to identify altered biological functions. Immunohistochemistry was used to further investigate a significant key regulatory protein.
Around 100 proteins were differently expressed in AppNL-F mice at each time point (3, 6, 9, and 18 months of age) as compared to wild type mice. Strikingly, already at 3 months of age-long before Aβ plaque development and memory impairment-several pathways, including long-term potentiation and synaptic plasticity, were downregulated, and neuritogenesis was increased. Huntingtin (HTT) was identified as an upstream regulator, i.e., a key protein affecting the levels of several proteins. Increased levels of HTT in hippocampus of AppNL-F mice was supported by immunofluorescence microscopy.
Notably, the proteome was significantly altered already at 3 months of age, 6 months before the development of plaques. Differentially expressed proteins varied over time, indicating that increased Aβ42 levels initiate a cascade of events that eventually manifests in amyloid depositions, inflammation, and decline in memory.
42 个氨基酸长的淀粉样β肽(Aβ42)可能引发一系列事件,导致阿尔茨海默病(AD)大脑中观察到的严重神经退行性变。然而,潜在的分子机制仍有待确定。
为了找到早期 Aβ42 诱导的 AD 相关机制,我们在一种新型的 App 敲入 AD 小鼠模型 AppNL-F 上进行了大脑蛋白质组学时间进程研究,该模型表达高水平的 Aβ42 而没有 AβPP 过表达的人工制品。
分别使用 18O 标记质谱分析海马体和皮质,以揭示蛋白质水平的变化。对蛋白质组学数据进行途径分析,以确定改变的生物学功能。免疫组织化学用于进一步研究一个重要的关键调节蛋白。
与野生型小鼠相比,AppNL-F 小鼠在每个时间点(3、6、9 和 18 个月)的蛋白质表达水平都有 100 多种不同。引人注目的是,早在 3 个月大——在 Aβ斑块形成和记忆障碍之前——几个途径,包括长时程增强和突触可塑性,就已经下调,而神经突生成增加。亨廷顿蛋白(HTT)被鉴定为上游调节剂,即影响几种蛋白质水平的关键蛋白。AppNL-F 小鼠海马体中 HTT 水平的增加得到免疫荧光显微镜的支持。
值得注意的是,蛋白质组在 3 个月大时就发生了显著改变,比斑块形成早 6 个月。差异表达的蛋白质随时间变化,表明 Aβ42 水平的升高引发了一系列事件,最终导致淀粉样沉积、炎症和记忆下降。